[go: up one dir, main page]

FR13C0034I1 - - Google Patents

Info

Publication number
FR13C0034I1
FR13C0034I1 FR13C0034C FR13C0034I1 FR 13C0034 I1 FR13C0034 I1 FR 13C0034I1 FR 13C0034 C FR13C0034 C FR 13C0034C FR 13C0034 I1 FR13C0034 I1 FR 13C0034I1
Authority
FR
France
Prior art keywords
compounds
amyloid deposits
methods
relates
making
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
Other languages
French (fr)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of FR13C0034I1 publication Critical patent/FR13C0034I1/fr
Application granted granted Critical
Publication of FR13C0034I2 publication Critical patent/FR13C0034I2/en
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
    • C07D211/94—Oxygen atom, e.g. piperidine N-oxide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/06—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom containing only hydrogen and carbon atoms in addition to the ring nitrogen atom
    • C07D213/16—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom containing only hydrogen and carbon atoms in addition to the ring nitrogen atom containing only one pyridine ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Communicable Diseases (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pyridine Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

This invention relates to a method of imaging amyloid deposits and to styrylpyridine compounds, and methods of making radiolabeled styrylpyridine compounds useful in imaging amyloid deposits. This invention also relates to compounds, and methods of making compounds for inhibiting the aggregation of amyloid proteins to form amyloid deposits, and a method of delivering a therapeutic agent to amyloid deposits.
FR13C0034C 2006-03-30 2013-06-26 STYRYLPYRIDINE DERIVATIVES AND THEIR APPLICATIONS TO AMYLOID PLAQUE BINDING AND IMAGING Active FR13C0034I2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US78715606P 2006-03-30 2006-03-30
PCT/US2007/007400 WO2007126733A2 (en) 2006-03-30 2007-03-26 Styrylpyridine derivatives and their use for binding and imaging amyloid plaques

Publications (2)

Publication Number Publication Date
FR13C0034I1 true FR13C0034I1 (en) 2013-08-09
FR13C0034I2 FR13C0034I2 (en) 2014-03-07

Family

ID=38326579

Family Applications (1)

Application Number Title Priority Date Filing Date
FR13C0034C Active FR13C0034I2 (en) 2006-03-30 2013-06-26 STYRYLPYRIDINE DERIVATIVES AND THEIR APPLICATIONS TO AMYLOID PLAQUE BINDING AND IMAGING

Country Status (34)

Country Link
US (3) US7687052B2 (en)
EP (3) EP2363392B1 (en)
JP (1) JP5290954B2 (en)
KR (1) KR101376807B1 (en)
CN (1) CN101522624B (en)
AT (1) ATE539060T1 (en)
AU (1) AU2007243712B2 (en)
BR (1) BRPI0710225B1 (en)
CA (1) CA2644530C (en)
CR (1) CR10329A (en)
CY (3) CY1113048T1 (en)
DK (2) DK2363392T3 (en)
EA (1) EA017898B1 (en)
EC (1) ECSP088783A (en)
ES (2) ES2378785T3 (en)
FR (1) FR13C0034I2 (en)
GT (1) GT200800201A (en)
HR (2) HRP20120135T1 (en)
HU (2) HUE032660T2 (en)
IL (1) IL193567A (en)
LT (1) LT2363392T (en)
LU (1) LU92232I2 (en)
MX (1) MX2008012527A (en)
NO (2) NO342090B1 (en)
NZ (1) NZ570887A (en)
PL (2) PL1999109T3 (en)
PT (2) PT2363392T (en)
RS (2) RS56171B1 (en)
SG (1) SG173338A1 (en)
SI (2) SI1999109T1 (en)
TW (1) TWI399366B (en)
UA (1) UA97802C2 (en)
WO (1) WO2007126733A2 (en)
ZA (1) ZA200807955B (en)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101522624B (en) * 2006-03-30 2013-11-06 宾夕法尼亚大学理事会 Styrylpyridine derivatives and their use for binding and imaging amyloid plaques
WO2009004914A1 (en) * 2007-07-04 2009-01-08 Tohoku University Pet probe having alkoxy group substituted by fluorine and hydroxy group
JP5603855B2 (en) * 2008-04-04 2014-10-08 アビッド レディオファーマシューティカルズ、インク． Imaging neurodegenerative diseases with radiopharmaceuticals
PL2381967T3 (en) * 2008-12-31 2017-06-30 Avid Radiopharmaceuticals, Inc. Synthesis of 18f-radiolabeled styrylpyridines from tosylate precursors and stable pharmaceutical compositions thereof
EP2451760A1 (en) * 2009-07-10 2012-05-16 Bayer Pharma Aktiengesellschaft Usage of low to medium-pressure liquid chromatography for the purification of radiotracers
US20120263646A1 (en) 2009-10-15 2012-10-18 Guerbet Imaging agents and their use for the diagnostic in vivo of neurodegenerative diseases, notably alzheimer's disease and derivative diseases
AR079687A1 (en) * 2009-12-23 2012-02-15 Bayer Schering Pharma Ag ADEQUATE FORMULATIONS FOR DIAGNOSIS FOR IMAGES WITH PET
WO2011141515A1 (en) 2010-05-14 2011-11-17 Bayer Pharma Aktiengesellschaft Diagnostic agents for amyloid beta imaging
US20140012032A1 (en) * 2010-06-04 2014-01-09 Piramal Imaging Sa Method for production of f-18 labeled amyloid beta ligands
CA2801530C (en) 2010-06-04 2017-09-12 Piramal Imaging Sa Method for production of f-18 labeled amyloid beta ligands
TWI504414B (en) 2010-06-04 2015-10-21 Bayer Schering Pharma Ag Method for production of f-18 labeled aβ ligands
AU2011260420A1 (en) * 2010-06-04 2013-01-10 Piramal Imaging Sa Method for production of F-18 labeled amyloid beta ligand
CN101891674B (en) * 2010-06-24 2012-11-14 山东大学 4-styryl pyridine compound and preparation method as well as application thereof
US9259495B2 (en) * 2010-10-12 2016-02-16 Mayo Foundation For Medical Education And Research Imaging of meningiomas using phenylbenzothiazole, stilbene, or biphenylalkyne derivatives
US20140079635A1 (en) * 2011-03-30 2014-03-20 Case Western Reserve University Molecular probes for detecting lipid composition
CN103491870B (en) 2011-04-21 2016-12-28 加利福尼亚大学董事会 Functionalized magnetic nanoparticles and in amyloid deposition and neurofibrillary tangles imaging purposes
CA2852840A1 (en) 2011-10-19 2013-04-25 Piramal Imaging Sa Improved method for production of f-18 labeled a.beta. ligands
AU2013263297B2 (en) 2012-04-10 2017-11-30 Lantheus Medical Imaging, Inc. Radiopharmaceutical synthesis methods
JP6099045B2 (en) * 2013-04-30 2017-03-22 国立大学法人京都大学 Triazolopyrimidine derivative compounds
JP6041751B2 (en) * 2013-05-07 2016-12-14 日本メジフィジックス株式会社 Styrylpyridine derivative compound
JP2014218454A (en) * 2013-05-07 2014-11-20 日本メジフィジックス株式会社 Styrylpyridine derivative compounds
CN103645254B (en) * 2013-11-28 2015-01-07 江苏省原子医学研究所 Method for analyzing content of A beta plaque developer precursor AV45
MX376163B (en) * 2014-05-13 2025-03-07 Hoffmann La Roche DEUTERATED HETEROCYCLIC COMPOUNDS AND THEIR USE AS IMAGING AGENTS.
EP3337475B1 (en) * 2015-08-18 2024-10-02 The Regents of The University of California Nitroxide containing amyloid binding agents for imaging and therapeutic uses
US10300155B2 (en) 2015-12-31 2019-05-28 Washington University Alpha-synuclein ligands
CN109400615B (en) * 2017-08-18 2021-07-16 上海交通大学医学院附属新华医院 A kind of coumarin compound targeting β-amyloid and its preparation and application
CN108299287A (en) * 2018-01-02 2018-07-20 北京师范大学 There is the N of high-affinity with A β plaque block2S2Class pyridyl group distyryl compound
CN114805190A (en) * 2022-06-08 2022-07-29 吉林大学第一医院 Double-column synthesis method of methylaniline Abeta protein developer
WO2024107620A1 (en) 2022-11-14 2024-05-23 Eli Lilly And Company Polymorphic forms of florbetapir precursor av-105

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992000963A1 (en) * 1990-07-12 1992-01-23 Yoshitomi Pharmaceutical Industries, Ltd. Styryl compounds and use thereof as medicine
JPH0545875A (en) * 1991-08-08 1993-02-26 Konica Corp Photosensitive composition
US6020436A (en) 1993-03-09 2000-02-01 The Chromaline Corporation Photosensitive resin composition
TW544448B (en) * 1997-07-11 2003-08-01 Novartis Ag Pyridine derivatives
US20030138374A1 (en) 2000-03-22 2003-07-24 Yukitsuda Kudo Image diagnosis probe based on substituted azobenzene or analogue thereof for disease attributable to amyloid accumulation and composition for image diagnosis containing the same
US8007954B2 (en) 2000-11-09 2011-08-30 The Trustees Of The University Of Pennsylvania Use of sulfur-containing fuels for direct oxidation fuel cells
JP2002182254A (en) 2000-12-18 2002-06-26 Fuji Photo Film Co Ltd Nonlinear optical material and method for manufacturing the same
DK1432453T3 (en) * 2001-08-27 2013-11-18 Univ Pennsylvania STYLE BENDER DERIVATIVES AND ITS USE FOR BINDING AND IMAGING AMYLOID PLAQUES
US7740772B2 (en) 2002-06-06 2010-06-22 The Trustees Of The University Of Pennsylvania Ceramic anodes and method of producing the same
WO2004016271A1 (en) * 2002-08-14 2004-02-26 Axxima Pharmaceuticals Ag Pyrimidones as antiviral agents
JP4482352B2 (en) 2004-03-11 2010-06-16 本田技研工業株式会社 Polymer electrolyte fuel cell
WO2006078384A2 (en) * 2004-12-17 2006-07-27 The Trustees Of The University Of Pennsylvania Stilbene derivatives and their use
DK2213652T3 (en) * 2004-12-17 2015-01-26 Univ Pennsylvania Stilbene AND USE THEREOF FOR BINDING AND IMAGING OF amyloid plaques
AU2006261917A1 (en) * 2005-06-24 2007-01-04 The Trustees Of The University Of Pennsylvania Radiolabeled-pegylation of ligands for use as imaging agents
CN101522624B (en) 2006-03-30 2013-11-06 宾夕法尼亚大学理事会 Styrylpyridine derivatives and their use for binding and imaging amyloid plaques
US20080253967A1 (en) 2007-04-13 2008-10-16 Kung Hank F Halo-Stilbene Derivatives And Their Use For Binding And Imaging Of Amyloid Plaques

Also Published As

Publication number Publication date
EA017898B1 (en) 2013-04-30
IL193567A (en) 2014-03-31
CY1119048T1 (en) 2018-01-10
CY2013024I2 (en) 2015-11-04
HUS1300028I1 (en) 2017-08-28
DK2363392T3 (en) 2017-07-03
CY2013024I1 (en) 2015-11-04
US20090123369A1 (en) 2009-05-14
WO2007126733A3 (en) 2008-03-06
BRPI0710225A2 (en) 2011-08-02
CN101522624A (en) 2009-09-02
CA2644530C (en) 2015-05-19
LT2363392T (en) 2017-07-25
UA97802C2 (en) 2012-03-26
LU92232I2 (en) 2013-08-26
EP2363392A1 (en) 2011-09-07
ATE539060T1 (en) 2012-01-15
CN101522624B (en) 2013-11-06
JP2009532349A (en) 2009-09-10
CA2644530A1 (en) 2007-11-08
NO342090B1 (en) 2018-03-19
US7687052B2 (en) 2010-03-30
WO2007126733A2 (en) 2007-11-08
MX2008012527A (en) 2008-10-14
TW200838852A (en) 2008-10-01
AU2007243712B2 (en) 2013-01-10
FR13C0034I2 (en) 2014-03-07
IL193567A0 (en) 2009-05-04
RS56171B1 (en) 2017-11-30
HRP20170857T1 (en) 2017-12-01
CY1113048T1 (en) 2015-11-04
AU2007243712A1 (en) 2007-11-08
US8840866B2 (en) 2014-09-23
GT200800201A (en) 2009-08-20
SG173338A1 (en) 2011-08-29
EP2363392B1 (en) 2017-05-03
ES2628882T3 (en) 2017-08-04
SI1999109T1 (en) 2012-04-30
EP1999109B1 (en) 2011-12-28
US8506929B2 (en) 2013-08-13
ZA200807955B (en) 2012-11-28
PL1999109T3 (en) 2012-05-31
PT2363392T (en) 2017-06-15
ECSP088783A (en) 2008-10-31
KR101376807B1 (en) 2014-03-20
US20080038195A1 (en) 2008-02-14
TWI399366B (en) 2013-06-21
PT1999109E (en) 2012-03-16
CR10329A (en) 2008-10-29
JP5290954B2 (en) 2013-09-18
HUE032660T2 (en) 2017-10-30
HRP20120135T1 (en) 2012-03-31
NO2018030I1 (en) 2018-09-11
DK1999109T3 (en) 2012-04-02
EP2363391A1 (en) 2011-09-07
LU92232I9 (en) 2019-01-15
NO20084590L (en) 2008-12-29
ES2378785T3 (en) 2012-04-17
EP1999109A2 (en) 2008-12-10
US20130129624A1 (en) 2013-05-23
KR20080106564A (en) 2008-12-08
EA200870389A1 (en) 2009-04-28
BRPI0710225B1 (en) 2021-07-13
NZ570887A (en) 2011-05-27
RS52222B (en) 2012-10-31
PL2363392T3 (en) 2017-10-31
SI2363392T1 (en) 2017-09-29

Similar Documents

Publication Publication Date Title
LU92232I9 (en)
MX2007007380A (en) Stilbene derivatives and their use for binding and imaging amyloid plaques.
WO2008073350A3 (en) Acetylene derivatives and their use for binding and imaging amyloid plaques
GB2443287B (en) Methods, compositions and formulations for the treatment of thyroid eye disease
EP2023926A4 (en) Pyridonecarboxamide derivatives useful in treating hyper-proliferative and angiogenesis disorders
WO2007033080A3 (en) Alzheimer's disease imaging agents
PT2050447T (en) An entacapone-containing oral dosage form
HUE059861T2 (en) N-substituted 2,5-dioxo-azoline compounds for use in the treatment of cancer
WO2008003943A3 (en) Inhibition of alpha-synuclein aggregation
ZA200803666B (en) Method for stabilising pharmaceutical administration forms that contain miro-organisms
PL2401263T3 (en) Substituted azole derivatives, pharmaceutical composition containing the derivatives, and method for treating parkinson's disease using the same
IL196561A0 (en) Compositions and methods for treating diabetes and neuropsychological dysfunction
WO2006078384A3 (en) Stilbene derivatives and their use
EP1846432A4 (en) Method for making targeted therapeutic agents
WO2006136454A3 (en) Use of inhibitors of n-methyl transferases for the therapy of parkinson's disease
WO2008050133A3 (en) Inhibition of beta-amyloid aggregation
EP1942909A4 (en) Methods for treating respiratory disorders
WO2010135493A3 (en) Alzheimer's disease imaging agents
UA91996C2 (en) Stilbene derivatives and their use for binding and imaging amyloid plaques
EP1937242A4 (en) Methods and compositions for the treatment of neuropsychiatric and addictive disorders
UA99579C2 (en) Antibody binding to tau phosphorylated at serine 422 (ps422) for use in the treatment of a tauopathy
IL184372A (en) Method for delivering interferon-ß
GB0620693D0 (en) Composition and methods for the treatment of degenerative disease
PL380320A1 (en) Method for the manufacture of 1,4-pregnadien-17,21-diol-3,20-dione